Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:37:07 ON 16 JUN 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:37:30 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0
DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-541504genA.str





```
chain nodes :
10  11  12  13  14  15  16  17  18  19  20  21  22  23  25  26
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
1-19  2-10  3-20  4-22  9-18  10-11  11-12  12-13  12-23  13-14  14-15  15-16
15-17  16-25  19-26  20-21
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9
exact/norm bonds :
1-19  3-20  5-7  6-9  7-8  8-9  9-18  15-16  15-17  16-25  19-26
exact bonds :
2-10  4-22  10-11  11-12  12-13  12-23  13-14  14-15  20-21
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


G1:H,Na

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS  25:CLASS  26:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 H,Na

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 18:38:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1058 TO ITERATE

100.0% PROCESSED 1058 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.01

L2 33 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 18:38:20 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 1728 L2

```
=> s l3 and crystalline
         83070 CRYSTALLINE
           270 CRYSTALLINES
         83318 CRYSTALLINE
                 (CRYSTALLINE OR CRYSTALLINES)
        372730 CRYST
          1802 CRYSTS
        373999 CRYST
                 (CRYST OR CRYSTS)
        401549 CRYSTALLINE
                 (CRYSTALLINE OR CRYST)
L4          12 L3 AND CRYSTALLINE

=> s l4 and oscillation
         68380 OSCILLATION
         73511 OSCILLATIONS
        116683 OSCILLATION
                 (OSCILLATION OR OSCILLATIONS)
L5           0 L4 AND OSCILLATION

=> s l4 and habit
         17585 HABIT
          8408 HABITS
         25071 HABIT
                 (HABIT OR HABITS)
L6           0 L4 AND HABIT

=> s l4 and acicular
          9394 ACICULAR
             7 ACICULARS
          9398 ACICULAR
                 (ACICULAR OR ACICULARS)
L7           0 L4 AND ACICULAR

=> d l4 1-12 abs ibib hitstr

L4   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2008 ACS on STN
GI
```



II



III



AB The invention relates to synthetic peptide amide ligands of the kappa opioid receptor Xaa1Xaa2Xaa3(Xaa4)a-G [I; Xaa1-Xaa3 = substituted D-amino acids; Xaa4 = D-amino acids, cis- and trans-α,4-diaminocyclohexaneacetic acid, cis- and trans-α-amino-4-guanidinocyclohexaneacetic acid, etc.; G = (Xaa1)m(Xaa2)n(Xaa3)p(Xaa4)qL; m-p = independently 0-1; q, a = independently 0-1, provided that at least one of q and a = 1; L = linker selected from ε-D-Lys, ε-Lys, δ-D-Orn, δ-Orn, γ-aminobutyric acid, 8-aminooctanoic acid, 11-aminoundecanoic acid, 8-amino-3,6-dioxaoctanoic acid,4-amino-4-piperidinecarboxylic acid, (D-LysGly lactam)2; or G = II; J = 5-7 membered heterocyclyl containing 1-3 heteroatoms in the ring; R3, R4 = independently alkyl, halo, OH, CF3, NH2, CO2H, amidino; R5, R6 = independently oxo, R3; W' = absent, provided that when W' = absent, Y = N; or W' = NH(CH2)b; b = 0-6 or W' = NH(CH2)cO; c = 2-3], their stereoisomers, mixture of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, N-oxides or isomorphic crystalline forms and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain for treatment of pain and inflammation associated with a variety of diseases and conditions. The invention also relates to synthetic peptide amide in which G = II; when G = II, a = 1, Xaa3-Xaa4- = D-Nle-(B)2D-Arg-, D-Leu-δ-(B)2α-(B')D-Orn-, (α-Me)D-Leu-δ(B)2-α(B')D-Orn-, and Y, Z = independently C, or N which are not adjacent ring atoms, provided that when such ring moiety is 6-8 membered ring, Y and Z are separated by at least 2 ring atoms and provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is nonarom.; W = one of W'; V = V'e; V' = alkyl and e = 0-1; when e = 0, V = absent and R1 and R2 are directly bonded to the same or different ring atoms; R1 = H, OH, halo, amidino, Pro-amide, alkyl, Lys, Arg, etc.; R2 = H, amidino, singly or doubly alkyl substituted amidino, CN, CONH2 and derivs., etc.; R1 and R2 taken together can form an optionally substituted 4-9 membered monocyclyl or bicyclyl heterocyclyl which is bonded to a single ring atom of the Y and Z-containing ring moiety; or R1 and R2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4-8 membered heterocyclic ring moiety to form a spiro structure; or R1 and R2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring

moiety can form an optionally substituted 4-9 membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety. Furthermore, when G = III, YZ = 4-8 membered heterocyclic ring, wherein Y = C or N and Z = C, N, O, S, SO, SO2, provided that when such ring moiety is 6-8 membered ring, Y and Z are separated by at least 2 ring atoms and provided that when such ring is nonarom. and Z = C or N then such ring moiety contains at least one S or O heteroatom, and provided further that when such ring is aromatic, then Y = C. Eleven biol. examples are given. Thus, peptide amide IV was prepared on 2-chlorotrityl chloride resin using Boc-D-Phe-OH, Fmoc-D-Phe-OH, Fmoc-D-Leu-OH, Fmoc-D-Orn(Boc)-OH, and 2-carboxy-4-[[(fluoren-9-yl)methoxy]carbonyl]morpholine. The potency of the peptide amides I as kappa opioid receptor agonists was determined by measuring the inhibition of forskolin-stimulated adenylate cyclase activity in mouse R1.G1 cells; EC50 = 0.178 nM and efficacy = 100% for IV. I and their pharmaceutical compns. are useful for treating visceral pain, neuropathic pain, hyperalgesia and inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma.

ACCESSION NUMBER: 2008:619334 CAPLUS

TITLE: Synthetic peptide amides and dimers as kappa opioid receptor agonists for treatment of pain and inflammation

INVENTOR(S): Schteingart, Claudio D.; Menzaghi, Frederique; Jiang, Guangcheng; Alexander, Roberta Vezza; Sueiras-Diaz, Javier; Spencer, Robert H.; Chalmers, Derek T.; Luo, Zhiyong

PATENT ASSIGNEE(S): Cara Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 158pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008060552	A2	20080522	WO 2007-US23874	20071113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
US 2006-858120P	P	20061110
US 2006-858121P	P	20061110
US 2006-858123P	P	20061110
US 2007-928527P	P	20070510
US 2007-928551P	P	20070510
US 2007-928557P	P	20070510

IT 24280-93-1D, Mycophenolic acid, derivs. and heterocylic aminoalkyl esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic peptide amide ligands of κ-opioid receptors useful in prophylaxis, treatment and combination therapy of pain and inflammation

associated with variety of diseases)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I



II

AB The invention relates to synthetic peptide amide ligands of the kappa opioid receptor I [Xaa1-Xaa3 = substituted D-amino acids; Xaa4 = D-amino acids, cis- and trans-α,4-diaminocyclohexaneacetic acid, cis- and trans-α-amino-4-guanidinocyclohexaneacetic acid; W = absent, provided that when W = absent, Y = N; or W = NH(CH2)m; m = 0-6 or W = NH(CH2)pO; p = 2-3, provided that Y= C; YZ = 4-8 membered heterocyclic ring, wherein all ring heteroatoms are N; Y, Z = independently C, N, provided that when such ring moiety is 6-8 membered ring, Y and Z are separated by at least 2 ring atoms and provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is nonarom.], their stereoisomers, mixture of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, N-oxides or isomorphic crystalline forms and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain for treatment of pain and inflammation associated with a variety of diseases and conditions. Sixteen biol. examples are given. Thus,peptide amide II was prepared on p-nitrophenylcarbonate Wang resin using Cbz-D-Phe-OH, Fmoc-D-Phe-OH, Fmoc-D-Leu-OH, Fmoc-Lys(Dde)-OH

[Dde = 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl] and homopiperazine. The potency of the peptide amides I as kappa opioid receptor agonists was determined by measuring the inhibition of forskolin-stimulated adenylate cyclase activity; EC50 = 0.043 nM and efficacy = 103% for II. I and their pharmaceutical comps. are useful for treating visceral pain, neuropathic pain, hyperalgesia and inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma.

ACCESSION NUMBER: 2008:585809 CAPLUS
DOCUMENT NUMBER: 148:562184
TITLE: Synthetic peptide amides as kappa opioid receptor agonists for treatment of pain and inflammation
INVENTOR(S): Schteingart, Claudio D.; Menzaghi, Frederique; Jiang, Guangcheng; Alexander, Roberta Vezza; Sueiras-Diaz, Javier; Spencer, Robert H.; Chalmers, Derek T.; Luo, Zhiyong
PATENT ASSIGNEE(S): Cara Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 132pp., which
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008057608	A2	20080515	WO 2007-US23858	20071113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-858109P P 20061110
US 2007-928550P P 20070510

IT 24280-93-1D, Mycophenolic acid, derivs. and heterocylic aminoalkyl esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic peptide amide ligands of κ-opioid receptors useful in prophylaxis and treatment and combination therapy of pain and inflammation associated with variety of diseases)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

AB Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula I: wherein R is selected from H or CH3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided. Also provided are depside and anthocyanin compds., pharmaceutical compns., unit dosage forms, and food or feed supplements containing such compds. Methods for treating a condition in a mammal and for treating or ameliorating a condition, such as for example, chronic obstructive pulmonary disease (COPD) by administering an effective amount of a composition containing such compds. are also provided. Further provided is an extract obtained from the fruit of Myrciaria cauliflora containing at least one compound of the present invention in substantially pure form.

ACCESSION NUMBER: 2008:160479 CAPLUS
DOCUMENT NUMBER: 148:206676
TITLE: Bioactive depside and anthocyanin compounds, compositions, and methods of use
INVENTOR(S): D'Armiento, Jeanine; Reynertson, Kurt; Kennelly, Edward; Wallace, Alison
PATENT ASSIGNEE(S): Trustees of Columbia University In the City of New York, USA
SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008016593	A2	20080207	WO 2007-US17087	20070731

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-834719P P 20060731

OTHER SOURCE(S): MARPAT 148:206676

IT 24280-93-1, Mycophenolic acid

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bioactive depside and anthocyanin compds. for modulation of chemokines and treatment of disease in relation to isolation from Myrciaria cauliflora and treatment with other agents)

RN 24280-93-1 CAPLUS

CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

GI



I



II

AB The present invention relates to erastin analogs, particularly compds. of formula I. The invention also relates to pharmaceutical compns. containing such analogs and to methods of treating a condition in a mammal with such analogs and compns. Compds. of formula I wherein R1 is H, C1-8 alkyl, C1-8 alkoxy, 3- to 8-membered carboxylic, and 3- to 8-membered heterocyclic, (hetero)aryl, etc.; R2, R3, R4, R5 and R6 are independently H, halo, C1-4 alkyl(amino), acyl, and alkylsulfonyl; and their enantiomers, optical isomers, diastereoisomers, N-oxides, crystalline forms, hydrates and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their anticancer activity.

ACCESSION NUMBER: 2007:763864 CAPLUS
DOCUMENT NUMBER: 147:166336
TITLE: Erastin analogs and their preparation, pharmaceutical compositions and use in the treatment of cancer and other conditions characterized by hyperproliferation of cells
INVENTOR(S): Stockwell, Brent R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 174pp., Cont.-in-part of Appl. No. PCT/US2006/002723.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070161644	A1	20070712	US 2006-492546	20060724
WO 2006081337	A2	20060803	WO 2006-US2723	20060125
WO 2006081337	A3	20070215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

WO 2008013840 A2 20080131 WO 2007-US16702 20070724

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-647372P P 20050125
WO 2006-US2723 A2 20060125
US 2006-762221P P 20060124
US 2006-492546 A 20060724

OTHER SOURCE(S): MARPAT 147:166336

IT 24280-93-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of erastin analogs and uses for treating cancer or other conditions characterized by hyperproliferation of cells)

RN 24280-93-1 CAPLUS

CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

AB A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphol. in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an elec. potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphol. of said pharmaceutical agent. Dry powder rapamycin was coated on an elec. charged 316 stainless steel metal coupon by the above method. The coupon was covered in a relatively even distribution of powdered material. X-ray

diffraction confirmed that the powdered material was largely crystalline in nature as deposited on the metal coupon.

ACCESSION NUMBER: 2007:83515 CAPLUS
DOCUMENT NUMBER: 146:190619
TITLE: Polymer coatings containing drug powder of controlled morphology
INVENTOR(S): Taylor, Doug; McClain, Jim; Smoke, Clint; Cole, Mike; Deyoung, James
PATENT ASSIGNEE(S): Micell Technologies, Inc., USA
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007011707	A2	20070125	WO 2006-US27321	20060714
WO 2007011707	A3	20071227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006270221	A1	20070125	AU 2006-270221	20060714
CA 2615452	A1	20070125	CA 2006-2615452	20060714
EP 1909973	A2	20080416	EP 2006-787258	20060714
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:

US 2005-699650P	P	20050715
US 2005-752338P	P	20051220
US 2006-771066P	P	20060207
US 2006-771725P	P	20060208
US 2006-745731P	P	20060426
US 2006-745733P	P	20060426
WO 2006-US27321	W	20060714

IT 24280-93-1, Mycophenolic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymer coatings containing drug powder of controlled morphol.)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

AB The invention relates to drug development and, more specifically, to designing compds. that modulate inosine monophosphate dehydrogenase (IMPDH). The invention provides a crystalline complex containing Tritrichomonas foetus IMPDH in complex with inosine monophosphate (IMP), the complex specified by disclosed atomic coordinates. Also provided are crystalline complexes of containing T. foetus IMPDH with both inosine monophosphate (IMP) and mycophenolic acid, with both xanthosine monophosphate (XMP) and mycophenolic acid, with both xanthosine monophosphate (XMP) and NAD, with ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), and with both ribavirin and mycophenolic acid, each complex specified by disclosed atomic coordinates. Also provided by the invention are the atomic coordinates for these complexes. Further provided by the invention are methods for identifying modulators of IMPDH that employ the atomic coordinates of the invention.

ACCESSION NUMBER: 2006:759515 CAPLUS
DOCUMENT NUMBER: 145:205118
TITLE: Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs, and drug design uses
INVENTOR(S): Luecke, Hartmut; Prosise, Glen
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: U.S., 349 pp., which
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 7083961	B1	20060801	US 2003-663347		20030915
PRIORITY APPLN. INFO.:			US 2002-410523P	P	20020913
			US 2002-412044P	P	20020918

IT 24280-93-1DP, Mycophenolic acid, complexes with inosine monophosphate dehydrogenase and ribavirin monophosphate
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs, and drug design uses)

RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB The use of a benzofuran to mask phenol and arylacetaldehyde moieties simultaneously in the synthesis of analogs of mycophenolic acid (MPA) was explored. Benzofuran I provided a stable and easily handled intermediate for the preparation of unnatural derivs. at the C-6 position of MPA. Preparation of the highly potent 6-Et MPA analog II was accomplished via aldehyde III through this facile route with high-yielding steps and crystalline intermediates.

ACCESSION NUMBER: 2006:530448 CAPLUS
DOCUMENT NUMBER: 145:210776
TITLE: Use of Benzofuran for Concomitant Protection of Aldehyde and Phenol Groups in the Preparation of Mycophenolic Acid Analogues
AUTHOR(S): Fardis, Maria; Mertzman, Michael; Thomas, William; Kirschberg, Thorsten; Collins, Nicole; Polniaszek, Richard; Watkins, William J.
CORPORATE SOURCE: Gilead Sciences, Foster City, CA, 94404, USA
SOURCE: Journal of Organic Chemistry (2006), 71(13), 4835-4839
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:210776
IT 24280-93-1, Mycophenolic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of mycophenolic acid analogs via use of benzofuran as protection of aldehyde and phenol groups)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
AB Provided are crystalline mycophenolate sodium forms and processes for their preparation Claimed are crystalline mycophenolate sodium form M4, M5, M6, M7, M8, M9, M10, M11, and M12, mycophenolate sodium acetone solvate, and mycophenolate sodium acetonitrile solvate.
ACCESSION NUMBER: 2006:103455 CAPLUS
DOCUMENT NUMBER: 144:177429
TITLE: Crystalline mycophenolate sodium
INVENTOR(S): Molnar, Sandor; Szabo, Csaba; Tamas, Tivadar; Hajko, Janos; Kovacsne-Mezei, Adrienne; Aronhime, Judith
PATENT ASSIGNEE(S): Teva Gyogyszergyar Reszvenytarsasag, Hung.; Teva Pharmaceuticals Usa, Inc.
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012385	A2	20060202	WO 2005-US25816	20050720
WO 2006012385	A3	20060622		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM

CA 2573784	A1	20060202	CA 2005-2573784		20050720
US 20060069150	A1	20060330	US 2005-186164		20050720
US 20060069152	A1	20060330	US 2005-186560		20050720
EP 1768969	A2	20070404	EP 2005-773805		20050720
CN 101052631	A	20071010	CN 2005-80023953		20050720
JP 2008506784	T	20080306	JP 2007-522726		20050720
EP 1908756	A1	20080409	EP 2007-23241		20050720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
IN 2006DN07646	A	20070817	IN 2006-DN7646		20061218
US 20080097096	A1	20080424	US 2007-2069		20071214
US 20080103317	A1	20080501	US 2007-2049		20071214
PRIORITY APPLN. INFO.:			US 2004-589909P	P	20040720
			US 2004-631849P	P	20041129
			EP 2005-775059	A3	20050720
			US 2005-186164	A3	20050720
			WO 2005-US25816	W	20050720

IT 23047-11-2P, Disodium mycophenolate 37415-62-6P, Mycophenolate sodium
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation of polymorphic forms of mycophenolate sodium and solvates thereof)

RN 23047-11-2 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, sodium salt (1:2), (4E)- (CA INDEX NAME)

Double bond geometry as shown.



●2 Na

RN 37415-62-6 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, sodium salt (1:1), (4E)- (CA INDEX NAME)

Double bond geometry as shown.



● Na

IT 24280-93-1, Mycophenolic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of polymorphic forms of mycophenolate sodium and solvates thereof)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



IT 874303-39-6 874303-40-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of polymorphic forms of mycophenolate sodium and solvates thereof)
RN 874303-39-6 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, monosodium salt, (4E)-, compd. with 2-propanone (9CI) (CA INDEX NAME)

CM 1

CRN 24280-93-1
CMF C17 H20 O6

Double bond geometry as shown.



CM 2

CRN 67-64-1
CMF C3 H6 O

RN 874303-40-9 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)-, monosodium salt, compd. with acetonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 37415-62-6
CMF C17 H20 O6 . Na

Double bond geometry as shown.



● Na

CM 2

CRN 75-05-8
CMF C2 H3 N

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

AB Provided are crystalline mycophenolate sodium forms and processes for their preparation A process for preparing anhydrous crystalline mycophenolate sodium (Form M2) comprises (1) preparing a solution of mycophenolic acid in a C1-4 alc., (2) combining a base and a source of sodium with the solution to obtain a reaction mixture, (3) crystallizing the mixture, and (4) recovering the crystalline form.

ACCESSION NUMBER: 2006:103454 CAPLUS
DOCUMENT NUMBER: 144:177428
TITLE: Processes for the preparation of crystalline mycophenolate sodium
INVENTOR(S): Molnar, Sandor; Szabo, Csaba; Tamas, Tivadar; Hajko, Janos; Kovacsne-Mezei, Adrienne; Aronhime, Judith
PATENT ASSIGNEE(S): Ceva Gyogyszergyar Reszvenytarsasag, Hung.; Teva Pharmaceuticals Usa, Inc.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012379	A2	20060202	WO 2005-US25808	20050720
WO 2006012379	A3	20060622		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, SI, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2573781	A1	20060202	CA 2005-2573781	20050720
US 20060069150	A1	20060330	US 2005-186164	20050720
US 20060069152	A1	20060330	US 2005-186560	20050720
EP 1699753	A2	20060913	EP 2005-775059	20050720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 101014584	A	20070808	CN 2005-80024065	20050720
JP 2008506783	T	20080306	JP 2007-522720	20050720
EP 1908756	A1	20080409	EP 2007-23241	20050720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080097096	A1	20080424	US 2007-2069	20071214
US 20080103317	A1	20080501	US 2007-2049	20071214

PRIORITY APPLN. INFO.:

US 2004-589909P	P	20040720
US 2004-631849P	P	20041129
EP 2005-775059	A3	20050720
US 2005-186164	A3	20050720
WO 2005-US25808	W	20050720

IT 37415-62-6P, Mycophenolate sodium
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of crystalline mycophenolate sodium)
RN 37415-62-6 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, sodium salt (1:1), (4E)- (CA INDEX NAME)

Double bond geometry as shown.



● Na

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
AB In our studies on new plant growth regulators from fungal metabolites, we found the growth suppressive substances against lettuce seedling in an Et acetate extract of the culture broth of an unidentified species of Penicilliumn. A bioactive substance (1) was isolated as crystalline solid by column chromatog. and preparative TLC, successively. This substance (1) was identified to mycophenolic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid with UV, IR and MS. At a concentration of 100 ppm and 1000 ppm, the substance (1) inhibited the lettuce root growth to 70% and 100% compared with the control, resp.
ACCESSION NUMBER: 2003:372844 CAPLUS
DOCUMENT NUMBER: 139:161860
TITLE: Plant growth regulator produced by Penicillium sp. (part 1)
AUTHOR(S): Adachi, Takuo; Katsuzaki, Hirotaka; Imai, Kunio; Komiya, Takashi
CORPORATE SOURCE: Faculty of Agriculture, Meijo University, Japan
SOURCE: Meijo Daigaku Nogakubu Gakujutsu Hokoku (2003), 39, 21-26
CODEN: MDNGBZ; ISSN: 0910-3376
PUBLISHER: Meijo Daigaku Nogakubu
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
IT 24280-93-1P, Mycophenolic acid
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(plant growth inhibitor produced by penicillium sp)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

AB mycophenolic acid (I) [24280-93-1] is produced by culturing Penicillium strains 1st in a conventional nutrient medium and then in a 2nd medium containing sugar in the absence of a metabolizable N source. Thus, a preculture of P. brevicompactum OM-8406 was 1st aerobically incubated in a medium (pH 4.5) containing glucose, peptone, KH2PO4, and MgSO4.7H2O at 26° for 72 h with stirring (800 rpm) and aeration. The cultured cells were isolated and reincubated in a 2nd medium (pH 4.5) containing glucose 2% and adenine 0.03% under similar condition for 96 h. The accumulation of I reached 579 mL/L. I was extracted from the acidified broth with CHCl3 and dried to obtain crystalline I. Similar I production was achieved when glucose was replaced by sucrose or fructose as the C sucrose.

ACCESSION NUMBER: 1982:33356 CAPLUS
DOCUMENT NUMBER: 96:33356
ORIGINAL REFERENCE NO.: 96:5505a,5508a
TITLE: Production of mycophenolic acid
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56127093	A	19811005	JP 1980-29247	19800310
PRIORITY APPLN. INFO.:			JP 1980-29247 A	19800310

IT 24280-93-1P
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(manufacture of, with Penicillium brevicompactum)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB A solution containing mycophenolic acid (I) [24280-93-1] is adjusted to pH <7 to crystalline I. Thus, 2 L of the fermented solution of Penicillium brevi-compactum containing 1 g I was maintained at 50° and the pH was adjusted to 3 with HCl. The solution was cooled gradually to 5° to precipitate 1.05 g crude crystals containing 0.97 g I.

ACCESSION NUMBER: 1980:443954 CAPLUS
DOCUMENT NUMBER: 93:43954
ORIGINAL REFERENCE NO.: 93:7277a,7280a
TITLE: Separation of mycophenolic acid
INVENTOR(S): Uchida, Hiroshi; Igarashi, Mieko; Kusumoto, Isao
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55019055	A	19800209	JP 1978-91987	19780727
PRIORITY APPLN. INFO.:			JP 1978-91987 A	19780727

IT 24280-93-1
RL: PROC (Process)
(crystallization of, from Penicillium brevi-compactum fermentation medium)
RN 24280-93-1 CAPLUS
CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (CA INDEX NAME)

Double bond geometry as shown.




```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      78.68     257.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -9.60      -9.60

FILE 'CAPLUS' ENTERED AT 18:44:30 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008  VOL 148 ISS 25
FILE LAST UPDATED: 15 Jun 2008  (20080615/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s "crystal habit" and acicular and "temperature oscillation"
       1391699 "CRYSTAL"
        690670 "CRYSTALS"
       1692513 "CRYSTAL"
                 ("CRYSTAL" OR "CRYSTALS")
         17585 "HABIT"
          8408 "HABITS"
         25071 "HABIT"
                 ("HABIT" OR "HABITS")
          3896 "CRYSTAL HABIT"
                 ("CRYSTAL"(W)"HABIT")
          9394 ACICULAR
             7 ACICULARS
          9398 ACICULAR
                 (ACICULAR OR ACICULARS)
```

```
        686431 "TEMPERATURE"
         84997 "TEMPERATURES"
        757585 "TEMPERATURE"
                 ("TEMPERATURE" OR "TEMPERATURES")
       3216633 "TEMP"
        810808 "TEMPS"
       3568967 "TEMP"
                 ("TEMP" OR "TEMPS")
       3752740 "TEMPERATURE"
                 ("TEMPERATURE" OR "TEMP")
         68380 "OSCILLATION"
         73511 "OSCILLATIONS"
        116683 "OSCILLATION"
                 ("OSCILLATION" OR "OSCILLATIONS")
          1148 "TEMPERATURE OSCILLATION"
                 ("TEMPERATURE"(W)"OSCILLATION")
L8             0 "CRYSTAL HABIT" AND ACICULAR AND "TEMPERATURE OSCILLATION"

=> s "crystal habit" and acicular
       1391699 "CRYSTAL"
        690670 "CRYSTALS"
       1692513 "CRYSTAL"
                 ("CRYSTAL" OR "CRYSTALS")
         17585 "HABIT"
          8408 "HABITS"
         25071 "HABIT"
                 ("HABIT" OR "HABITS")
          3896 "CRYSTAL HABIT"
                 ("CRYSTAL"(W)"HABIT")
          9394 ACICULAR
             7 ACICULARS
          9398 ACICULAR
                 (ACICULAR OR ACICULARS)
L9            80 "CRYSTAL HABIT" AND ACICULAR

=> s l9 and "temperature gradient"
        686431 "TEMPERATURE"
         84997 "TEMPERATURES"
        757585 "TEMPERATURE"
                 ("TEMPERATURE" OR "TEMPERATURES")
       3216633 "TEMP"
        810808 "TEMPS"
       3568967 "TEMP"
                 ("TEMP" OR "TEMPS")
       3752740 "TEMPERATURE"
                 ("TEMPERATURE" OR "TEMP")
        213215 "GRADIENT"
         65708 "GRADIENTS"
        259037 "GRADIENT"
                 ("GRADIENT" OR "GRADIENTS")
         29921 "TEMPERATURE GRADIENT"
                 ("TEMPERATURE"(W)"GRADIENT")
L10            0 L9 AND "TEMPERATURE GRADIENT"

=> s "crystal habit" and "temperature oscillation"
       1391699 "CRYSTAL"
        690670 "CRYSTALS"
       1692513 "CRYSTAL"
                 ("CRYSTAL" OR "CRYSTALS")
         17585 "HABIT"
          8408 "HABITS"
         25071 "HABIT"
```

```
                ("HABIT" OR "HABITS")
          3896 "CRYSTAL HABIT"
                ("CRYSTAL"(W)"HABIT")
        686431 "TEMPERATURE"
         84997 "TEMPERATURES"
        757585 "TEMPERATURE"
                ("TEMPERATURE" OR "TEMPERATURES")
       3216633 "TEMP"
        810808 "TEMPS"
       3568967 "TEMP"
                ("TEMP" OR "TEMPS")
       3752740 "TEMPERATURE"
                ("TEMPERATURE" OR "TEMP")
         68380 "OSCILLATION"
         73511 "OSCILLATIONS"
        116683 "OSCILLATION"
                ("OSCILLATION" OR "OSCILLATIONS")
          1148 "TEMPERATURE OSCILLATION"
                ("TEMPERATURE"(W)"OSCILLATION")
L11          2 "CRYSTAL HABIT" AND "TEMPERATURE OSCILLATION"

=> d l11 1-2 abs ibib

L11  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AB   The crystal growth rate is mainly determined by diffusion in the vapor phase.
     The limitation of the growth process by transport leads to a continuous
     change of the growth conditions, which is the cause of slowing down the
     growth and the change of the growth rates ratio of the crystallog.
     different faces, the latter evokes refaceting.  The limitation of the
     growth by the transport process is the factor reducing the perfection of
     the structure and the maximum sizes of single crystals.
ACCESSION NUMBER:         1985:176745  CAPLUS
DOCUMENT NUMBER:          102:176745
ORIGINAL REFERENCE NO.:   102:27645a,27648a
TITLE:                    Stability of growth conditions and α-mercury(II)
                          iodide crystal habit during
                          growing by temperature oscillation
                          method
AUTHOR(S):                Zaletin, V. M.; Lyakh, N. V.; Ragozina, N. V.
CORPORATE SOURCE:         Inst. Semicond. Phys., Novosibirsk, 630090, USSR
SOURCE:                   Crystal Research and Technology (1985), 20(3), 307-12
                          CODEN: CRTEDF; ISSN: 0232-1300
DOCUMENT TYPE:            Journal
LANGUAGE:                 English

L11  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AB   cf. C.A. 46, 9923f.  Crystals of NaCl were immersed in saturated solution in
     closed vessels containing excess NaCl in the bottom.  The temperature was
oscillated
     over ranges of 0.1, 2, and 5° around 20° in various expts.
     The period of the temperature oscillation was 20 min.  The
     vessels were either provided with Hg-sealed stirrers or else were held in
     a mech. shaker.  The expts. lasted about 3 days for ΔT = 5°,
     about 2 weeks for ΔT = 0.1°.  At the end of the expts.,
     crystals originally cubes (001) exhibited faces 001, 111, 012, (011?).
     Crystals originally octahedra (111) (from solns. containing urea) exhibited
     faces 111, 001, 012, 011.  Crystals originally dodecahedra (011) (from
     solns. containing glycine) exhibited faces 011, 001, 111, (012?).  Faces 011
     and 012 were striated parallel to cube edges.  The nature of the new faces
     was independent of ΔT and of the original shape.  No limiting
     end-form could be recognized.  It was concluded that the faces listed are
     among those which grow by repeatable steps.
```

ACCESSION NUMBER:	1952:64699 CAPLUS
DOCUMENT NUMBER:	46:64699
ORIGINAL REFERENCE NO.:	46:10771f-h
TITLE:	Modification of the habit of sodium chloride crystals in saturated solution under the influence of temperature oscillations
AUTHOR(S):	Honigmann, B.
CORPORATE SOURCE:	Kaiser-Wilhelm Inst., Berlin-Dahlem
SOURCE:	Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie (1952), 56, 342-5 CODEN: ZEAPAA; ISSN: 0372-8323
DOCUMENT TYPE:	Journal
LANGUAGE:	Unavailable

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 18:56:57 ON 16 JUN 2008